Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2020, Pancreatic Adenocarcinoma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 26 Dec 2019.

  2. Mackay TM, et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB (Oxford). 2020;22(2):233–40.

    Article  Google Scholar 

  3. Merkow RP, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7.

    Article  Google Scholar 

  4. Adam MA, et al. Neoadjuvant chemotherapy for pancreatic adenocarcinoma lessens the deleterious effect of omission of adjuvant chemotherapy. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-020-09446-x.

Download references

Author information

Authors and Affiliations

  1. Division of Liver, Biliary, and Pancreatic Surgery, University of California, San Francisco, CA, USA

    Mohamed Abdelgadir Adam MD

  2. Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

    Alessandro Paniccia MD

Authors
  1. Mohamed Abdelgadir Adam MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Paniccia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Abdelgadir Adam MD.

Ethics declarations

Disclosure

Mohamed Abdelgadir Adam and Alessandro Paniccia declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adam, M.A., Paniccia, A. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Ann Surg Oncol 28, 3808–3809 (2021). https://doi.org/10.1245/s10434-020-09487-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09487-2

Search

Navigation